Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2003
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodesMonic J Stuart, William P Peters, Gloria Broadwater, et al.Cancer|April 30, 2009
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant gliomaJennifer A Quinn, Sara Xiaoyin Jiang, David A Reardon, et al.Cancer|June 11, 2009
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapyMary Lou Affronti, Christopher R Heery, James E Herndon, et al.Journal of Neuro-Oncology|June 30, 2009
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.Cancer Medicine|May 2, 2013
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastomaEmil Lou, Katherine B Peters, Ashley L Sumrall, et al.Journal of Neuro-Oncology|April 27, 2012
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective seriesEmil Lou, Ashley L Sumrall, Scott Turner, et al.International Journal of Radiation Oncology, Biology, Physics|November 2, 2010
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiformeJames J Vredenburgh, Annick Desjardins, John P Kirkpatrick, et al.Cancer|May 19, 2011
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyDavid A Reardon, Annick Desjardins, Katherine B Peters, et al.Journal of Neuro-Oncology|September 21, 2010
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyDavid A Reardon, Annick Desjardins, Katherine Peters, et al.Leukemia & Lymphoma|August 1, 2002
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaSteven L McCune, Jon P Gockerman, Joseph O Moore, et al.Pageof 11